Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer. [PDF]
PLoS ONE, 2013 Despite optimal radiation therapy (RT), chemotherapy and/or surgery, a majority of patients with locally advanced non-small cell lung cancer (NSCLC) fail treatment. To identify novel gene targets for improved tumor control, we performed whole genome RNAi
Kyle R Cron +8 more
doaj +1 more source
Assembly of the Drosophila 26 S proteasome is accompanied by extensive subunit rearrangements [PDF]
, 2002 The subunit contacts in the regulatory complex of the Drosophila 26 S proteasome were studied through the cross-linking of closely spaced subunits of the complex, and analysis of the cross-linking pattern in an immunoblot assay with the use of subunit ...
Kapelari, Barbara +13 more
core +2 more sources
Inhibition of proteasomal degradation of rpn4 impairs nonhomologous end-joining repair of DNA double-strand breaks. [PDF]
PLoS ONE, 2010 BACKGROUND: The proteasome homeostasis in Saccharomyces cerevisiae is regulated by a negative feedback circuit in which the transcription factor Rpn4 induces the proteasome genes and is rapidly degraded by the assembled proteasome.
Donghong Ju +4 more
doaj +1 more source
Dss1 Is a 26S Proteasome Ubiquitin Receptor [PDF]
, 2014 The ubiquitin-proteasome system is the major pathway for protein degradation in eukaryotic cells. Proteins to be degraded are conjugated to ubiquitin chains that act as recognition signals for the 26S proteasome.
Hardwick, Kevin G. +20 more
core +1 more source
Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure
EBioMedicine, 2015 The proteasome inhibitor Bortezomib is used to treat multiple myeloma (MM). Bortezomib inhibits protein degradation by inactivating proteasomes' active-sites. MM cells are exquisitely sensitive to Bortezomib – exhibiting a low-nanomolar IC50 – suggesting
David S. Pitcher +5 more
doaj +1 more source
Experimental and computational analysis of polyglutamine-mediated cytotoxicity. [PDF]
PLoS Computational Biology, 2010 Expanded polyglutamine (polyQ) proteins are known to be the causative agents of a number of human neurodegenerative diseases but the molecular basis of their cytoxicity is still poorly understood.
Matthew Y Tang +3 more
doaj +1 more source
Proteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: Opportunity for combination therapy. [PDF]
PLoS ONE, 2018 Triple negative breast cancer (TNBC) cells express increased levels of the pro-inflammatory and pro-angiogenic chemokine interleukin-8 (IL-8, CXCL8), which promotes their proliferation and migration.
Mohammad M Uddin +4 more
doaj +1 more source
Cells, 2021 Proteasomes are intracellular structures responsible for protein degradation. The 20S proteasome is a core catalytic element of the proteasome assembly.
Elmira Vagapova +8 more
doaj +1 more source
Proteasome inhibition in hematologic malignancies
Annals of Medicine, 2004 Hematologic malignancies, including multiple myeloma (MM), will account for more than 100,000 new cases of cancer and over 57,000 deaths in the United States in 2003. Treatment of MM is a serious challenge, because despite a variety of available therapies, median survival is short.
Paul G, Richardson +3 more
openaire +2 more sources
Evaluation of the NRF1-proteasome axis as a therapeutic target in breast cancer
Scientific Reports, 2023 Proteasomes are multi-subunit complexes that specialize in protein degradation. Cancer cells exhibit a heightened dependence on proteasome activity, presumably to support their enhanced proliferation and other cancer-related characteristics.
Holly A. Byers +7 more
doaj +1 more source